Featuring online engagement, assessment and scheduling, as well as in-person clinical testing and logistics, TourHealth is a scalable COVID-19 testing solution that promises rapid results.
The TourHealth partnership has been awarded a contract by the State of Florida to provide two semi-permanent testing sites in city of Miami and Miami Beach.
At each site, TourHealth will be able to process up to 625 tests per day for a total of 1,250 tests daily.
In Utah, the TourHealth partnership was selected as one of two vendors approved for a multi-vendor contract vehicle to provide scheduling, call center and test collection relating to COVID-19 testing for state agencies, local governments and educational institutions.
Under the TourHealth partnership, NIC will provide its Gov2Go technology solution, a mobile platform and personal government assistant, for citizen engagement, assessment and scheduling purposes.
Impact Health will supply credentialled clinical professionals to staff the testing units and provide testing results quickly and securely to individuals and government, integrating results with government contact tracing programs. Next Marketing will be responsible for onsite logistics, including supplying mobile testing units, site design, signage and operational support, as applicable.
NIC (NASDAQ: EGOV) is a leading digital government solutions and payments company, serving more than 7,000 federal, state and local government agencies across the nation.
Impact Health is in providing field-based health and wellness services and has led efforts to combat the COVID-19 pandemic through temperature scanning and testing with various FDA/EUA approved kits.
Impact Health supports both private and public sector clients including Yale New Haven Health, Ashley Furniture, CBS Broadcasting and the State of Kansas.
Next Marketing is in developing, executing and managing mobile tour solutions for corporate and government clients including the US Air Force, Air National Guard, General Motors, and Continental Tire.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval